| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-02-19 | Vivalis (France) Kyoto Biken (Japan) |
EB66® cell line for the production of viral vaccines | licensing |
See details |
| 2010-02-18 | Swedish Orphan Biovitrum (Sweden) BiogenIdec (USA) |
recombinant Factor VIII Fc fusion protein (rFVIIIFc) recombinant Factor IX Fc fusion protein (rFIXFc) / Hemophilia A and B |
R&D licensing commercialization/ distribution development marketing/ promotion other |
See details |
| 2010-02-18 | Galapagos (Belgium) Morphosys (Germany) |
antibody therapeutics / bone & joint diseases, including rheumatoid arthritis, osteoporosis and osteoarthritis | R&D development |
See details |
| 2010-02-17 | Roche Molecular Systems (Switzerland-USA) Merck & Co (USA) |
AmpliChip p53 Test / cancers harboring a dysfunctional p53 gene | R&D licensing other |
See details |
| 2010-02-17 | Aureus-Pharma (France) Sanofi-Aventis (France) |
DDI Predict 2009 Edition (risk analysis of potential drug-drug interactions) | R&D other |
See details |
| 2010-02-16 | Rigel Pharmaceuticals (USA) AstraZeneca (UK) |
fostamatinib disodium (R788) (oral Spleen Tyrosine Kinase (Syk) inhibitor) / rheumatoid arthritis and additional indications |
commercialization/ distribution development |
See details |
| 2010-02-16 | Philogen (Italy) Bayer HealthCare Manufacturing (Germany) |
manufacturing |
See details | |
| 2010-02-16 | immatics biotechnologies (Germany) Cancer Research UK (UK) |
therapeutic cancer vaccine IMA950 It consists of 11 tumour-associated peptides (TUMAPs) which the immatics platform selects on the basis of their natural presentation by tumour tissue, immunogenicity and their relevance to tumour function. / glioblastoma |
other |
See details |
| 2010-02-09 | Debiopharm (Switzerland) Novartis (Switzerland) |
Debio 025 (alisporivir - synthetic first-in-class cyclophilin inhibitor) / hepatitis C | licensing commercialization/ distribution development marketing/ promotion |
See details |
| 2010-02-08 | Active Biotech (Sweden) Teva Pharmaceutical Industries (Israel) |
laquinimod / relapsing-remitting multiple sclerosis | commercialization/ distribution marketing/ promotion |
See details |
| 2010-02-08 | Johns Hopkins University (USA) Qiagen (The Netherlands) |
biomarker PI3K / cancer | licensing |
See details |
| 2010-02-05 | Therapure Biopharma (Canada) LFB Biomedicaments (France) |
undisclosed plasma proteins including coagulation factors | manufacturing |
See details |
| 2010-02-05 | DxS, subsidiary of Qiagen (The Netherlands) Pfizer (USA) |
companion diagnostic test kit for the immunotherapy vaccine PF-04948568 (CDX-110). PF-04948568 is a 14 amino acid peptide chemically conjugated to Keyhole Limpet Hemocyanin (KLH). It is targeting the tumor specific epidermal growth factor receptor (EGFR) mutant EGFRvIII. On April 16, 2008, Pfizer Vaccines LLC. has been granted an exclusive worldwide license to the product. A phase II study is ongoing in patients with glioblastoma multiforme (ACT III) (See clintrials.gov). / glioblastoma multiforme |
licensing development |
See details |
| 2010-02-04 | Ariana Pharma (France) Fovea Pharmaceuticals (France) |
services (Phase II clinical data analysis using KEM® (Knowledge Extraction and Management) decision support platform ) | other |
See details |
| 2010-02-04 | Massachusetts General Hospital (USA) Harvard University (USA) Roche (Switzerland) |
cellular models of disease based on human stem cell lines / metabolic disorders and cardiovascular diseases | R&D other |
See details |
